Board of Directors
Governance and strategic direction from experienced leaders across pharmaceutical services, clinical development and investment.
Strategic Oversight and Governance
The Evestia Clinical Board brings together leaders with decades of experience in pharmaceutical services, clinical development and investment. The Board provides governance and strategic direction to support the continued growth of Evestia Clinical's global clinical development capabilities.
The Board is distinct from the operational Leadership team, focusing on governance, strategic priorities and organizational growth.
Meet the Board
Richard Barfield
Chairman
Richard has over 12 years in pharmaceutical services, serving as CFO at Chiltern International and Ergomed plc. He has more than 30 years' CFO-level experience across healthcare, technology and business services.
Lewis Cameron
Chief Executive Officer
Lewis has over 25 years' experience in preclinical and clinical drug development with a strong focus on oncology and rare diseases.
Roy Ovel
Chief Commercial Officer
Roy has over 35 years' experience in the pharmaceutical industry, leading commercial teams across a wide range of geographical territories.
Carl Hvass
Chief Financial Officer
A Fellow of the Institute of Chartered Accountants with more than 20 years' senior finance experience in the CRO sector.
Adam Maidment
Managing Partner, Kester Capital
Adam co-founded Kester Capital and sits on its Investment Committee. Previously a partner at Greenhill Capital Partners Europe and Silverfleet Capital. He graduated from Trinity College, Oxford.
Thomas Holroyd
Partner, Kester Capital
Thomas joined Kester Capital in 2021 after 7 years in private equity at Chiltern Capital and Vitruvian Partners. He graduated from the University of Cambridge and is a Chartered Accountant.
Paul Bishop
Chief Development Officer
Paul co-founded Atlantic Research Group and led it to 10 years of record growth before merging with Evestia Clinical.
Board profiles are editable. Additional board members can be added as approved information becomes available.